Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain
- First Posted Date
- 2006-03-13
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 44
- Registration Number
- NCT00301847
- Locations
- 🇺🇸
Ingalls Cancer Care Center at Ingalls Memorial Hospital, Harvey, Illinois, United States
🇺🇸Central Illinois Hematology Oncology Center, Springfield, Illinois, United States
🇺🇸Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Carcinoma, Non-Small Cell Lung
- Interventions
- First Posted Date
- 2006-03-10
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 926
- Registration Number
- NCT00300885
BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma
- First Posted Date
- 2006-02-06
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10
- Registration Number
- NCT00287495
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
- Conditions
- Stage IV MelanomaRecurrent Melanoma
- Interventions
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 109
- Registration Number
- NCT00281957
- Locations
- 🇺🇸
Contra Costa Regional Medical Center, Martinez, California, United States
🇺🇸El Camino Hospital, Mountain View, California, United States
🇺🇸Great Falls Clinic, Great Falls, Montana, United States
Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
- Conditions
- Anaplastic Large Cell LymphomaRecurrent Mantle Cell LymphomaRecurrent Adult Diffuse Large Cell Lymphoma
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2006-01-18
- Last Posted Date
- 2013-02-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 33
- Registration Number
- NCT00278382
- Locations
- 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
- Conditions
- Gastrointestinal Stromal Tumor
- Interventions
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 38
- Registration Number
- NCT00265798
- Locations
- 🇺🇸
Central Illinois Hematology Oncology Center, Springfield, Illinois, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Decatur Memorial Hospital, Decatur, Illinois, United States
Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2014-11-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 53
- Registration Number
- NCT00259129
Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00255658
- Locations
- 🇺🇸
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas, United States
Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Refractory Multiple Myeloma
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00253578
- Locations
- 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States
Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer
- Conditions
- Adenocarcinoma of the Gastroesophageal JunctionMetastatic Gastric CancerAdvanced Unresectable Gastric Cancer
- Interventions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2014-11-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 44
- Registration Number
- NCT00253370
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.